Qi Qi

Qi Qi

Auto-generated profile, based on publicly available information

Qi Qi

Department of Physiology and Pharmacology, Western University, London, ON, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Stem Cells International
Verified
Journal Article
Open access
XSXiao-Yu Shi
Xiao-Yu Shi
Kun ZhangKun Zhang
Kun Zhang
FYFengshi Yu
Fengshi Yu
QQQi Qi
Qi Qi
YCYu xiao Cai
Yu xiao Cai
YZYu Zhang
Yu Zhang
The effectiveness and safety of mesenchymal stem cell (MSC) therapy have been substantiated across various diseases. Nevertheless, challenges such as the restricted in vitro expansion capacity of tissue‐derived MSCs and the clinical instability due to the high heterogeneity of isolated cells require urgent resolution. The induced pluripotent stem cell‐derived MSCs (iPSC‐MSCs), which is differentiated from iPSCs via specific experimental pathways, holds considerable potential as a substitute for tissue derived MSCs. Multiple studies have demonstrated that iPSCs can be differentiated into iPSC‐MSCs through diverse differentiation strategies. Research suggests that iPSC‐MSCs, when compared to tissue derived MSCs, exhibit superior characteristics in terms of proliferation ability, immune modulation capacity, and biological efficiency. In this review, we meticulously described and summarized the experimental methods of iPSC differentiation into iPSC‐MSCs, the application of iPSC‐MSCs in various disease models, the latest advancements in clinically relevant iPSC‐derived cell products, and the development strategies for the next generation of iPSC‐derived therapy products (not only cell products but also their derivatives).

13 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
FNFabrice Ngoh Njotu
Fabrice Ngoh Njotu
HBHanan Babeker
Hanan Babeker
AMAlissar Monzer
Alissar Monzer
ENEmmanuel Nwangele
Emmanuel Nwangele
HFHumphrey fonge
Humphrey fonge
Purpose: There is overwhelming interest to use actinium-225 ([225Ac]Ac) to develop targeted α therapies. Antibody–drug conjugates (ADC) are highly cytotoxic. Combining [225Ac]Ac with an ADC to develop an antibody–drug radioconjugate [225Ac]Ac–macropa–trastuzumab(T)–PEG6–emtansine (DM1), is expected to be more effective than its ADC (T–PEG6–DM1) against breast cancer. Experimental Design: [89Zr]Zr–p-isothiocyanatobenzyl desferrioxamine (DFO)–T–PEG6–DM1 (imaging) and [225Ac]Ac–macropa–T–PEG6–DM1 (radiotherapy) were developed. Biodistribution and safety evaluations of [225Ac]Ac–macropa–T-PEG6–DM1 were carried out in non–tumor-bearing BALB/c mice. MicroPET imaging and biodistribution were done using [89Zr]Zr-DFO–T–PEG6–DM1, and radiotherapy using [225Ac]Ac–macropa–T–PEG6–DM1 was carried out in athymic BALB/c nude mice bearing trastuzumab-resistant HCC1954 and trastuzumab-DM1 (T-DM1)/trastuzumab-resistant JIMT-1 tumor-bearing mice. Results: After 7 days of incubation at 37°C, [225Ac]Ac–macropa–T–PEG6–DM1 was stable in both human serum (89.2% ± 0.9%) and PBS (82.8% ± 0.4%). T–PEG6–DM1 (8 mg/kg) and [225Ac]Ac–macropa–T–PEG6–DM1 (3 × 18 kBq) administered separately in non–tumor-bearing mice 10 days apart were well tolerated biochemically and hematologically. Imaging and biodistribution showed high tumor uptake of [89Zr]Zr-DFO–T–PEG6–DM1 in tumor-bearing mice at 120 hours after injection: 38.1% ± 2.8% IA/g (HCC1954) and 14.6% ± 1% IA/g (JIMT-1). In HCC1954 tumor-bearing mice, all treatment groups had complete remission (8/8), indicative of the responsiveness of the xenograft to T-DM1–based treatments, whereas for JIMT-1 xenografts (having 1/8 complete remission) at 23 days after treatment, tumor volumes were 332.1 ± 77.5 vs. 244.6 ± 63 vs. 417.9 ± 62.1 vs. 102.4 ± 18.5 for the saline (negative control), T-DM1 (positive control), T–PEG6–DM1, and [225Ac]Ac–macropa–T–PEG6–DM1, respectively. Conclusions: [225Ac]Ac–macropa–T–PEG6–DM1 is more potent than ADC against trastuzumab-resistant breast cancer and necessitates clinical translation.

28 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KOKate M. Onuska
Kate M. Onuska
HSHayley R.C. Shanks
Hayley R.C. Shanks
LDLauren A. Devito
Lauren A. Devito
QQQi Qi
Qi Qi
ACAlycia M. Crooks
Alycia M. Crooks
TSTaylor W. Schmitz
Taylor W. Schmitz
Synaptic dysfunction is a hallmark of Alzheimer’s disease (AD). Yet due to their plasticity, synapses may also adapt to early AD pathology. Here, we demonstrate that cholinergic neurons mount a presynaptic response to tau pathology in the living human brain. Using multi-tracer positron emission tomography in cognitively normal older adults at risk for AD, we observe that cholinergic neurons increase presynaptic vesicular acetylcholine transporter (VAChT) protein levels when colocalized to tau, but not amyloid. Notably, stronger VAChT responses were associated with cognitive resilience over a decade. Whole-brain single-nucleus RNA sequencing in human and mouse tissue reveal that cholinergic neurons are enriched for a plasticity gene-network anchored to the microtubule-associated protein tau ( MAPT ) gene. In mice, forebrain-specific deletion of VAChT impairs cortical plasticity and hippocampal structural integrity. Overall, our findings identify cholinergic synaptic plasticity, and its failure, as a fundamental mechanism of resilience and vulnerability to tau in presymptomatic AD.

17 February 2025
Verified
Other
Open access
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
FNFabrice Ngoh Njotu
Fabrice Ngoh Njotu
HBHanan Babeker
Hanan Babeker
AMAlissar Monzer
Alissar Monzer
ENEmmanuel Nwangele
Emmanuel Nwangele
HFHumphrey fonge
Humphrey fonge
Supplementary Fig. S3: Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in non-reduced conditions for trastuzumab and its conjugates showing good chemical purity and structural integrity of the antibody.

17 February 2025
Verified
Other
Open access
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
FNFabrice Ngoh Njotu
Fabrice Ngoh Njotu
HBHanan Babeker
Hanan Babeker
AMAlissar Monzer
Alissar Monzer
ENEmmanuel Nwangele
Emmanuel Nwangele
HFHumphrey fonge
Humphrey fonge
Supplementary Table S3: Blood chemistry panel for toxicity of [225Ac]Ac-Macropa-T-PEG6-DM1 in non-tumor bearing Balb/C mice

17 February 2025
Verified
Other
Open access
PDF file
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
FNFabrice Ngoh Njotu
Fabrice Ngoh Njotu
HBHanan Babeker
Hanan Babeker
AMAlissar Monzer
Alissar Monzer
ENEmmanuel Nwangele
Emmanuel Nwangele
HFHumphrey fonge
Humphrey fonge
Supplementary Fig. S1: MALDI-TOF- matrix-assisted laser desorption ionization-time of flight mass spectrometry of trastuzumab, T-PEG6-DM1, and macropa-T-PEG6-DM1 was used to determine the drug-to-antibody ratio (DAR) and the chelator-to-antibody ratio (CAR) for Macropa.